Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Triprolidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 2/20 | 0.95 |
| ▸ | LMNA | P02545 | 3/20 | 0.98 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.98 |
| ▸ | GMNN | O75496 | 1/20 | 0.98 |
| ▸ | BLM | P54132 | 1/20 | 0.98 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.95 |
| ▸ | MEN1 | O00255 | 3/20 | 0.95 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.95 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.95 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.95 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.95 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.95 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.95 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.95 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.95 |
| ▸ | TSHR | P16473 | 1/20 | 0.95 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.95 |
| ▸ | THPO | P40225 | 1/20 | 0.95 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triprolidine SCHEMBL29730199 | 1.00 | LMNA (0.98) | LMNANPSR1GMNNBLMPMP22 | |
| Triprolidine SCHEMBL1140976 | 1.00 | LMNA (0.98) | LMNANPSR1GMNNBLMPMP22 | |
| Triprolidine SCHEMBL9723510 | 0.99 | LMNA (1.00) | LMNANPSR1GMNNBLMPMP22 | |
| Triprolidine SCHEMBL42146 | 0.99 | LMNA (1.00) | LMNANPSR1GMNNBLMPMP22 | |
| Triprolidine SCHEMBL42145 | 0.99 | LMNA (1.00) | LMNANPSR1GMNNBLMPMP22 | |
| Triprolidine SCHEMBL14973526 | 0.98 | KMT2A (0.95) | LMNANPSR1GMNNBLMPMP22 | |
| Triprolidine SCHEMBL3881294 | 0.97 | KMT2A (1.00) | LMNANPSR1GMNNBLMPMP22 | |
| Triprolidine SCHEMBL4905 | 0.97 | KMT2A (1.00) | LMNANPSR1GMNNBLMPMP22 | |
| Triprolidine SCHEMBL29631820 | 0.97 | KMT2A (1.00) | LMNANPSR1GMNNBLMPMP22 | |
| Triprolidine SCHEMBL4906 | 0.97 | KMT2A (1.00) | LMNANPSR1GMNNBLMPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8350045-B2 | Process for preparation of E-isomer of 1-(4-methylphenyl)-1-(2-pyridyl)-3-pyrrolidino prop-1-ene and acid addition salts thereof | HIKAL LIMITED (IN) | 2013-01-08 | — | — | US | claimed |
| US-8350045-B2 | Process for preparation of E-isomer of 1-(4-methylphenyl)-1-(2-pyridyl)-3-pyrrolidino prop-1-ene and acid addition salts thereof | HIKAL LIMITED (IN) | 2013-01-08 | — | — | US | disclosed |
| US-20110046384-A1 | PROCESS FOR PREPARATION OF E-ISOMER OF 1-(4-METHYLPHENYL) - 1-(2-PYRID YL)-3-PYRROLIDINO PROP-1-ENE AND ACID ADDITION SALTS THEREOF | HIKAL LIMITED (IN) | 2011-02-24 | — | — | US | disclosed |
| US-20070123571-A1 | Use of a compound in the treatment of sleep disorders | BOOTS HEALTHCARE INTERNATIONAL LIMITED (GB) | 2007-05-31 | — | — | US | disclosed |
| US-20070026051-A1 | Use of tripolidine in providing refreshedness on waking | RECKITT BENCKISER HEALTHCARE (UK) LIMITED (GB) | 2007-02-01 | — | — | US | disclosed |
| US-20070015800-A1 | Use of a compound in providing refreshedness on waking and a method for the treatment of drowsiness therewith | THE BOOTS COMPANY PLC (GB) | 2007-01-18 | — | — | US | disclosed |
| WO-2005123074-A9 | USE OF A COMPOUND IN THE TREATMENT OF SLEEP DISORDERS | BOOTS HEALTHCARE INT LTD (GB) | 2006-12-14 | — | — | WO | disclosed |
| CN-1842334-A | Use of a compound in the treatment of sleep disorders | BOOTS HEALTHCARE INT LTD (GB) | 2006-10-04 | — | — | CN | disclosed |
| EP-1660082-A1 | USE OF A COMPOUND IN THE TREATMENT OF SLEEP DISORDERS | Boots Healthcare International Limited (GB) | 2006-05-31 | — | — | EP | disclosed |
| EP-1638562-A1 | USE OF TRIPOLIDINE IN PROVIDING REFRESHEDNESS ON WAKING | The Boots Company PLC (GB) | 2006-03-29 | — | — | EP | disclosed |
| WO-2004105758-A1 | USE OF TRIPOLIDINE IN PROVIDING REFRESHEDNESS ON WAKING | THE BOOTS COMPANY PLC (GB) | 2004-12-09 | — | — | WO | disclosed |
| EP-1455786-A1 | USE OF A COMPOUND IN THE TREATMENT OF SLEEP DISORDERS AND THE LIKE IN PROVIDING REFRESHEDNESS ON WAKING AND A METHOD FOR THE TREATMENT OF GROGGINESS THEREWITH | The Boots Company PLC (GB) | 2004-09-15 | — | — | EP | disclosed |
| US-20040029927-A1 | Use of a compound in providing refreshedness on waking and a method for the treatment of grogginess therewith | THE BOOTS COMPANY PLC (GB) | 2004-02-12 | — | — | US | disclosed |
| US-20030134878-A1 | Use of a compound in providing refreshedness on waking and a method for the treatment of drowsiness therewith | RECKITT BENCKISER HEALTHCARE (UK) LIMITED (GB) | 2003-07-17 | — | — | US | disclosed |
| WO-2003047580-A1 | USE OF A COMPOUND IN THE TREATMENT OF SLEEP DISORDERS AND THE LIKE, IN PROVIDING REFRESHEDNESS ON WAKING AND A METHOD FOR THE TREATMENT OF GROGGINESS THEREWITH | THE BOOTS COMPANY PLC (GB) | 2003-06-12 | — | — | WO | disclosed |
| US-6245785-B1 | MIXING WITH IONIZING COMPOUND; BIOAVAILABILITY | WARNER LAMBERT COMPANY | 2001-06-12 | — | — | US | disclosed |
| WO-2000032173-A1 | IMPROVED DISSOLUTION OF TRIPROLIDINE HYDROCHLORIDE | WARNER-LAMBERT COMPANY (US) | 2000-06-08 | — | — | WO | disclosed |
| EP-0038979-B1 | PROCESS FOR PREPARING ETHYLCELLULOSE MICROCAPSULES | Tanabe Seiyaku Co., Ltd. (JP) | 1984-07-11 | — | — | EP | disclosed |
| US-4411933-A | CYCLOHEXANE, ORGANOSILICON POLYMER, DISPERSION, CORES | TANABE SEIYAKU CO., LTD. (JP) | 1983-10-25 | — | — | US | disclosed |
| EP-0038979-A1 | Process for preparing ethylcellulose microcapsules | Tanabe Seiyaku Co., Ltd. (JP) | 1981-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046384-A1 | PROCESS FOR PREPARATION OF E-ISOMER OF 1-(4-METHYLPHENYL) - 1-(2-PYRID YL)-3-PYRROLIDINO PROP-1-ENE AND ACID ADDITION SALTS THEREOF | ENPP1, ELP1, ECE1 | HRH1 2554/4885LMNA 892/4885NPSR1 2635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.